Assessing Treatment Options For Patients with Anemia Secondary to Myelofibrosis
Episodes
Specialty:
All
All 503B Compounding Pharmacy Allergy Biosimilars Cardiovascular Health Chronic Kidney Disease Classical Hematology Dermatology Endocrinology Eye Care Future of Pharmacy Gastrointestinal Health Hematology Hepatitis/MASH Infectious Disease Neurology Oncology Pain Management Pediatrics Psychiatry Pulmonology Rheumatology Vaccines Veterinary Pharmacy Vitamins and Supplements Weight Management Women's Health
EP. 1: Understanding Myelofibrosis and the Central Role of JAK Pathway Dysregulation By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore expert insights on managing myelofibrosis, focusing on anemia, JAK inhibitors, and enhancing patient care for better outcomes.
EP. 2: Clinical Manifestations and Prognostic Impact of Anemia in Myelofibrosis By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Oncology pharmacists discuss myelofibrosis management, focusing on anemia, JAK inhibitors, and improving patient outcomes through tailored care.
EP. 3: Risk Stratification and the Evolving Role of Biomarkers in Myelofibrosis By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore the critical role of patient characteristics and biomarker testing in managing myelofibrosis, enhancing prognosis and treatment strategies.
EP. 4: Long-Term Consequences of Myelofibrosis and the Impact of Early Intervention By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore the long-term effects of myelofibrosis and the importance of early diagnosis and treatment for better patient outcomes.
EP. 5: Evolving Therapeutic Approaches and Unmet Needs Leading to JAK Inhibitors in Myelofibrosis By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore the evolution of myelofibrosis treatments, from traditional therapies to groundbreaking JAK inhibitors, and the ongoing need for innovative solutions.
EP. 6: FDA-Approved JAK Inhibitors in Myelofibrosis: Mechanisms, Indications, and Clinical Impact By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore the latest advancements in JAK inhibitors for myelofibrosis, highlighting their unique mechanisms and clinical implications for patient care.
EP. 7: Clinical Evidence and Impact of Newer JAK Inhibitors in Myelofibrosis By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore the latest advancements in myelofibrosis treatments, including Fedratinib, Pacritinib, and Momelotinib, and their clinical impacts.
EP. 8: Real-World Insights and Personalized Approaches with JAK Inhibitors in Myelofibrosis By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore how real-world evidence shapes myelofibrosis treatment, focusing on biomarker utilization and safety profiles of JAK inhibitors.
EP. 9: Future Directions for JAK Inhibitor Research in Myelofibrosis By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Experts discuss the need for improved clinical trials in myelofibrosis, focusing on disease modification, patient outcomes, and potential new therapies.
EP. 10: The Critical Role of Pharmacists in Optimizing JAK Inhibitor Therapy for Myelofibrosis By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Pharmacists play a crucial role in managing myelofibrosis treatment, ensuring patient education, medication access, and monitoring for adverse effects.
EP. 11: Incorporating Novel Data into Clinical Practice By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP New findings on myelofibrosis treatments reveal the impact of anemia on survival and the benefits of momelotinib for transfusion independence.
EP. 12: Emerging Therapies and the Evolving Role of Pharmacists in Myelofibrosis Management By Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, C. Brooke Adams, PharmD, BCOP , Ami Ali, PharmD, BCOP, Katherine Tobon, PharmD, BCOP Explore the latest advancements in myelofibrosis therapies, including innovative treatments and the evolving role of pharmacists in patient care.
